Specialisation
Retina and Vitreous.
Full title
Randomised, active-controlled, parallel group, phase III trial on the efficacy, safety and tolerability of 2 mg aflibercept administered with intyravidial injections using two different regimens of treatment for subjects with neovascular age-related macular degeneration.
Promoter
Bayer.
Start date
January 2016
End date
October 2017
Researchers
Principal: Dr Anniken Burés.